WARNING
Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents.
In experimental animals, minoxidil caused several kinds of myocardial lesions as well as other adverse cardiac effects (see Cardiac Lesions in Animals).
Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. It must also usually be given with a diuretic, frequently one acting in the ascending limb of the loop of Henle, to prevent serious fluid accumulation. Patients with malignant hypertension and those already receiving guanethidine (see WARNINGS) should be hospitalized when minoxidil is first administered so that they can be monitored to avoid too rapid, or large orthostatic, decreases in blood pressure.
|
MINOXIDIL SUMMARY
Minoxidil
Tablets USP
Rx only
Minoxidil tablets contain minoxidil, an antihypertensive peripheral vasodilator. Minoxidil occurs as a white to off-white, crystalline powder, soluble in alcohol and propylene glycol; sparingly soluble in methanol; slightly soluble in water; practically insoluble in chloroform, acetone and ethyl acetate.
Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.
Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of whom had hypertension that could not be controlled by other drugs.
|
MINOXIDIL NEWS HIGHLIGHTS
Media Articles Related to Minoxidil
MINOXIDIL-TOPICAL, Rogaine, Ronoxidil
Source: MedicineNet Alopecia Areata Specialty [2005.03.02]
Minoxidil: An Underused Vasodilator for Resistant or Severe Hypertension
Source: Medscape Pharmacotherapy Headlines [2004.06.16]
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
Source: MedicineNet Brain Tumor Specialty [2008.09.30]
Study Finds Antioxidant Deficiency Linked To Pulmonary Hypertension
Source: Hypertension News From Medical News Today [2008.09.24]
Vitamin C Might Help Lower Hypertension
Source: MedicineNet High Blood Pressure Specialty [2008.09.22]
Published Studies Related to Minoxidil
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. [2007.11]
A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. [2007.01]
K+ channel activation with minoxidil stimulates nasal-epithelial ion transport and blunts exaggerated hypoxic pulmonary hypertension. [2006.03]
Treatment of anal fissures using a combination of minoxidil and lignocaine: a randomized, double-blind trial. [2005.07]
Clinical Trials Related to Minoxidil
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss [Completed]
Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss [Recruiting]
Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension [Recruiting]
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss [Completed]
|
